Intravenous immunoglobulin-induced osmotic nephrosis

Nasimul Ahsan, Biff F. Palmer, Don Wheeler, Ralph G. Greenlee, Robert D. Toto

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Intravenous immunoglobulin preparations are being used for an increasing number of indications in clinical medicine. To minimize adverse reactions, sugar additives such as sucrose are added to some preparations to serve as stabilizing agents. We describe a patient treated with an immunoglobulin preparation containing sucrose who developed a fully reversible form of acute renal failure with histologic changes characterized by vacuolization and swelling of renal proximal tubular cells. We believe the high concentration of sucrose in the immunoglobulin preparation resulted in osmotic injury to the renal tubules. Such changes, which are identical to those described in humans and experimental animals given intravenous infusions of hypertonic sucrose, have come to be known as osmotic nephrosis. Risk factors for the development of this lesion are renal insufficiency and volume depletion. The risk for such injury can be minimized by further diluting the immunoglobulin preparation and slowing the infusion rate.

Original languageEnglish (US)
Pages (from-to)1985-1987
Number of pages3
JournalArchives of Internal Medicine
Volume154
Issue number17
DOIs
StatePublished - Sep 12 1994

Fingerprint

Nephrosis
Intravenous Immunoglobulins
Sucrose
Immunoglobulins
Kidney
Excipients
Clinical Medicine
Wounds and Injuries
Acute Kidney Injury
Intravenous Infusions
Renal Insufficiency

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Intravenous immunoglobulin-induced osmotic nephrosis. / Ahsan, Nasimul; Palmer, Biff F.; Wheeler, Don; Greenlee, Ralph G.; Toto, Robert D.

In: Archives of Internal Medicine, Vol. 154, No. 17, 12.09.1994, p. 1985-1987.

Research output: Contribution to journalArticle

Ahsan, Nasimul ; Palmer, Biff F. ; Wheeler, Don ; Greenlee, Ralph G. ; Toto, Robert D. / Intravenous immunoglobulin-induced osmotic nephrosis. In: Archives of Internal Medicine. 1994 ; Vol. 154, No. 17. pp. 1985-1987.
@article{3789ba17bff4473fac8331fef1ba3a27,
title = "Intravenous immunoglobulin-induced osmotic nephrosis",
abstract = "Intravenous immunoglobulin preparations are being used for an increasing number of indications in clinical medicine. To minimize adverse reactions, sugar additives such as sucrose are added to some preparations to serve as stabilizing agents. We describe a patient treated with an immunoglobulin preparation containing sucrose who developed a fully reversible form of acute renal failure with histologic changes characterized by vacuolization and swelling of renal proximal tubular cells. We believe the high concentration of sucrose in the immunoglobulin preparation resulted in osmotic injury to the renal tubules. Such changes, which are identical to those described in humans and experimental animals given intravenous infusions of hypertonic sucrose, have come to be known as osmotic nephrosis. Risk factors for the development of this lesion are renal insufficiency and volume depletion. The risk for such injury can be minimized by further diluting the immunoglobulin preparation and slowing the infusion rate.",
author = "Nasimul Ahsan and Palmer, {Biff F.} and Don Wheeler and Greenlee, {Ralph G.} and Toto, {Robert D.}",
year = "1994",
month = "9",
day = "12",
doi = "10.1001/archinte.154.17.1985",
language = "English (US)",
volume = "154",
pages = "1985--1987",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "17",

}

TY - JOUR

T1 - Intravenous immunoglobulin-induced osmotic nephrosis

AU - Ahsan, Nasimul

AU - Palmer, Biff F.

AU - Wheeler, Don

AU - Greenlee, Ralph G.

AU - Toto, Robert D.

PY - 1994/9/12

Y1 - 1994/9/12

N2 - Intravenous immunoglobulin preparations are being used for an increasing number of indications in clinical medicine. To minimize adverse reactions, sugar additives such as sucrose are added to some preparations to serve as stabilizing agents. We describe a patient treated with an immunoglobulin preparation containing sucrose who developed a fully reversible form of acute renal failure with histologic changes characterized by vacuolization and swelling of renal proximal tubular cells. We believe the high concentration of sucrose in the immunoglobulin preparation resulted in osmotic injury to the renal tubules. Such changes, which are identical to those described in humans and experimental animals given intravenous infusions of hypertonic sucrose, have come to be known as osmotic nephrosis. Risk factors for the development of this lesion are renal insufficiency and volume depletion. The risk for such injury can be minimized by further diluting the immunoglobulin preparation and slowing the infusion rate.

AB - Intravenous immunoglobulin preparations are being used for an increasing number of indications in clinical medicine. To minimize adverse reactions, sugar additives such as sucrose are added to some preparations to serve as stabilizing agents. We describe a patient treated with an immunoglobulin preparation containing sucrose who developed a fully reversible form of acute renal failure with histologic changes characterized by vacuolization and swelling of renal proximal tubular cells. We believe the high concentration of sucrose in the immunoglobulin preparation resulted in osmotic injury to the renal tubules. Such changes, which are identical to those described in humans and experimental animals given intravenous infusions of hypertonic sucrose, have come to be known as osmotic nephrosis. Risk factors for the development of this lesion are renal insufficiency and volume depletion. The risk for such injury can be minimized by further diluting the immunoglobulin preparation and slowing the infusion rate.

UR - http://www.scopus.com/inward/record.url?scp=0028129450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028129450&partnerID=8YFLogxK

U2 - 10.1001/archinte.154.17.1985

DO - 10.1001/archinte.154.17.1985

M3 - Article

C2 - 8074604

AN - SCOPUS:0028129450

VL - 154

SP - 1985

EP - 1987

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 17

ER -